These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14647910)

  • 1. [Antibody-induced failure of botulinum toxin therapy].
    Dressler D
    Nervenarzt; 2003 Dec; 74(12):1098-104. PubMed ID: 14647910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity.
    Dressler D; Pan L; Adib Saberi F
    J Neural Transm (Vienna); 2018 Oct; 125(10):1481-1486. PubMed ID: 30066275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological aspects of botulinum toxin therapy.
    Dressler D; Bigalke H
    Expert Rev Neurother; 2017 May; 17(5):487-494. PubMed ID: 27852103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy.
    Dressler D; Bigalke H
    Mov Disord; 2002 Jan; 17(1):170-3. PubMed ID: 11835457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin for treatment of dystonia.
    Dressler D
    Eur J Neurol; 2010 Jul; 17 Suppl 1():88-96. PubMed ID: 20590814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of botulinum toxin short interval therapy using incobotulinumtoxin A.
    Dressler D; Saberi FA
    J Neural Transm (Vienna); 2017 Apr; 124(4):437-440. PubMed ID: 27747444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-induced failure of botulinum toxin type B therapy in de novo patients.
    Dressler D; Bigalke H
    Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?
    Dressler D; Münchau A; Bhatia KP; Quinn NP; Bigalke H
    Eur Neurol; 2002; 47(2):118-21. PubMed ID: 11844901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.
    Dressler D; Hallett M
    Eur J Neurol; 2006 Feb; 13 Suppl 1():11-5. PubMed ID: 16417592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.
    Dressler D; Lange M; Bigalke H
    Mov Disord; 2005 Dec; 20(12):1617-9. PubMed ID: 16078216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of non-A botulinum toxins: botulinum toxin type B.
    Dressler D; Eleopra R
    Neurotox Res; 2006 Apr; 9(2-3):121-5. PubMed ID: 16785108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
    Greene PE; Fahn S
    Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological aspects of therapeutic botulinum toxin preparations].
    Dressler D
    Nervenarzt; 2006 Aug; 77(8):912-21. PubMed ID: 16810528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.
    Greene PE; Fahn S
    Mov Disord; 1993 Oct; 8(4):479-83. PubMed ID: 8232357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of therapeutic botulinum toxin preparations.
    Dressler D; Benecke R
    Disabil Rehabil; 2007 Dec; 29(23):1761-8. PubMed ID: 18033601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical relevance of botulinum toxin antibodies].
    Dressler D
    Nervenarzt; 2008 Jun; 79 Suppl 1():36-40. PubMed ID: 18927965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
    Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
    Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.